Prestige Consumer Healthcare Reports $290.3M Revenue and $61.0M Net Income for Q4 2024

Prestige Consumer Healthcare Inc. reported a total revenue of $290.3 million for the three months ended December 31, 2024, marking an increase of $7.6 million, or 2.7%, compared to $282.7 million for the same period in 2023. The company's net income for the quarter was $61.0 million, up from $53.0 million a year earlier, resulting in diluted earnings per share of $1.22, compared to $1.06 in the prior year. For the nine months ended December 31, 2024, total revenues decreased slightly to $841.2 million from $848.4 million in the previous year, while net income rose to $164.5 million from $159.9 million.

The North American OTC Healthcare segment saw a revenue increase of $2.4 million, or 1.0%, primarily driven by growth in the Gastrointestinal and Dermatologicals categories, despite a decline in the Cough & Cold category. Conversely, the International OTC Healthcare segment experienced a more significant revenue increase of $5.2 million, or 11.3%, largely due to strong sales in the Gastrointestinal category. The overall gross profit for the quarter was $161.0 million, a 2.0% increase from the previous year, although the gross profit margin slightly decreased to 55.5% from 55.9%, attributed to rising supply chain costs.

In terms of operational developments, Prestige Consumer Healthcare completed the acquisition of Hydralyte intellectual property for $8.3 million during the nine months ended December 31, 2024. The company also announced the appointment of Christine Sacco as Chief Operating Officer, effective January 6, 2025. The company’s employee headcount remained stable, with no significant changes reported in staffing levels.

The company continues to face challenges related to economic conditions, including supply chain disruptions and rising input costs, which have affected product availability and pricing. Prestige Consumer Healthcare noted that these factors could impact future sales and operational efficiency. Looking ahead, the company anticipates that its cash flow from operations, combined with existing credit facilities, will be sufficient to meet its working capital and capital expenditure needs over the next twelve months. As of December 31, 2024, the company had cash and cash equivalents of $50.9 million, reflecting a $4.4 million increase from the previous fiscal year.